Ampersand Capital Partners, a private equity firm specializing in growth equity investments in the life sciences and healthcare sectors, today announced a minority investment in Syft Technologies Limited, a world leading provider of Mass Spectrometry (SIFT-MS) solutions. Ampersand’s investment will allow Syft to accelerate their progress in the semiconductor market and develop the next scalable opportunity in life sciences.
Canterbury, New Zealand-based Syft develops SIFT-MS, a form of direct mass spectrometry that analyses volatile organic compounds (VOCs) in air with typical detection limits at parts-per-trillion level (by volume; pptv). Realtime, quantitative analysis is achieved by applying precisely controlled soft chemical ionization and eliminating sample preparation, pre-concentration and chromatography. Syft’s SIFT-MS instrumentation is industry-proven, providing non-technical operators with laboratory-grade chemical analysis presented in a format that they can understand and act on.
Read more: PR Newswire
